Bariatric Times

MAR 2017

A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional

Issue link:

Contents of this Issue


Page 0 of 28

C l i n i c a l D e v e l o p m e n t s a n d M e t a b o l i c I n s i g h t s i n T o t a l B a r i a t r i c P a t i e n t C a r e Volume 14, Number 3 March 2017 A P e e r - R e v i e w e d P u b l i c a t i o n W W W . B A R I A T R I C T I M E S . C O M LIKE us on Facebook • FOLLOW us on Twitter • CONNECT with us on LinkedIn Presorted Standard U.S. Postage PAID Lebanon Junction, KY Permit #344 DOWNLOAD OR UPDATE THE BARIATRIC TIMES APP TODAY! ITunes Google (Android) Download the BT app for your mobile device! Scan this QR code with your QR reader for the digital edition of Bariatric Times. EDITORIAL MESSAGES ................3 A Message from Dr. Raul J. Rosenthal: "Medical Treatment of any Disease Process, including Obesity, Should Always be Our First Choice" A Message from Dr. Christopher Still: Another Important Contributor to Obesity in the United States: Drug-Induced Weight Gain/Weight Loss Hindrance Inside IN M EM ORIAM . ... ... ... ... ... ... ... ... 10 In M e moriam: Ge orge L. Blac kburn, M D, P hD IN TERVIEW . ... ... ... ... ... ... ... ... ... .. 12 METABOLIC SURGERY IS HERE TO STAY: Five-Year Data Released Demonstrating Continued Durability, Superiority of Glycemic Control after Metabolic Surgery THE MEDICAL STUDENT NOTEBOOK . ... ... ... ... ... .... .. .... ... .. 16 Bariatric Surgery and Pseudotumor Cerebri NEWS AND TRENDS . ... ... ... ... ... . 24 CALENDAR OF EVENTS ................26 CARTOON CORNER ...................... 26 MARKETPLACE ........................... 26 AD INDEX ....................................27 INTERVIEW Page 16 COLUMN EDITOR Daniel B. Jones, MD, MS, FASMBS FEATURED STUDENT Leith Hathout, BS Bariatric Surgery and Pseudotumor Cerebri INTRODUCTION Obesity, defined as having a body mass index (BMI) of 30kg/m2 or more, is an increasingly prevalent disease. In the United States, 34.9 percent of adults and approximately 20 percent of adolescents have obesity. 1,2 Additionally, it is estimated that the prevalence of obesity in adults in the United States will increase to greater than 44 percent by 2030 and the prevalence of obesity worldwide continues to increase as well. 3,4 As is well known, obesity increases risk for several comorbidities, including many common metabolic, cardiovascular, respiratory, musculoskeletal, and gastrointestinal disorders. These comorbidities not only increase the overall disease burden of obesity in patients but also increase the financial burden on the healthcare system. 5 T h e M E D I C A L S T U D E N T N o t e b o o k Page 12 T he STAMPEDE (Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently) trial is the largest single center randomized trial with one of the longest follow-ups comparing medical therapy with bariatric surgery. Last month, Philip Schauer, MD, lead author, presented the STAMPEDE trial's final results during the American College of Cardiology's 65th Annual Scientific Session (ACC.16). 1 Recently, final five-year data was published in New England Journal of Medicine. 2 STAMPEDE is a three-arm controlled trial conducted by investigators from Cleveland Clinic, Cleveland, Ohio, that randomized 150 patients with obesity and uncontrolled type 2 diabetes mellitus (T2DM) to receive either intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass (RYGB) or laparoscopic sleeve gastrectomy (LSG). METABOLIC SURGERY IS HERE TO STAY Five-Year Data Released Demonstrating Continued Durability, Superiority of Glycemic Control after Metabolic Surgery A n I n t e r v i e w w i t h SANGEETA KASHYAP, MD Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Staff Physician, Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio.

Articles in this issue

Archives of this issue

view archives of Bariatric Times - MAR 2017